Rein Therapeutics Inc RNTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics to Present at Upcoming September Investor Conferences
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $0.61
- Day Range
- $0.59–0.59
- 52-Week Range
- $0.55–2.07
- Bid/Ask
- $0.58 / $0.60
- Shares Outstanding
- 86.27M
- Market Cap
- $50.03M
- Volume/Avg
- 3,087 / 414,892
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 10
- Website
- https://www.reintx.com
Valuation
Metric | RNTX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 5.15 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RNTX |
|---|---|
Quick Ratio | 4.19 |
Current Ratio | 4.27 |
Interest Coverage | — |
Quick Ratio
RNTX
Profitability
Metric | RNTX |
|---|---|
Return on Assets (Normalized) | −41.82% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RNTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|P@%<<Pm | LOCK|%f#x@ | $138B | |||
| Moderna Inc MRNA | LOCK|VNj^c#N | LOCK|$h | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|m<F>!C | LOCK|&#w#t | $93B | |||
| argenx SE ADR ARGX | LOCK|cjx%#S | LOCK|tJ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|>$^Xc%R | LOCK|zC | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?w%TL!bR | LOCK|@gMD | $30B | |||
| Incyte Corp INCY | LOCK|p#@>^JD | LOCK|<^F | $24B | |||
| BioNTech SE ADR BNTX | LOCK|Mvwwlf | LOCK|BX? | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|TgF^>$s | LOCK|bFMDf | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|FfC$qKN | LOCK|zT | $15B |
United States